Sanofi Ireland

Leadership as listed on sanofi.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on sanofi.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on sanofi.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Sanofi (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 166 in our ClinicalTrials.gov registers · 18 in the EU register

Showing 10 of 166, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 3 registry names

Drugs in these trials 82 compounds

EU trials register (CTIS) 18 authorised or ongoing

• An open-label, DDI study to investigate the effects of duvakitug on the PK of selected cytochrome P450 substrates2026-525939-17-00 · Phase I · Authorised
• An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD).2024-511508-18-00 · Phase I/II · Ongoing
• Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function2026-525707-27-00 · Phase I · Authorised
• A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS)2025-521268-37-00 · Phase IV · Ongoing
• A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age2025-521740-38-00 · Phase I/II · Authorised
• A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).2025-523403-29-00 · Phase II · Authorised
• A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients2025-521521-33-00 · Phase III · Ongoing
• A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)2026-526177-42-00 · Phase II · Authorised

Recent approvals

• CenrifkiEMA · tolebrutinib · 19 Jun 2026
• SupemtekEMA · trivalent influenza vaccine (recombinant, prepared in cell culture) · 30 Mar 2026
• RezurockEMA · belumosudil · 24 Mar 2026
• TeizeildEMA · teplizumab · 8 Jan 2026
• WayrilzEMA · rilzabrutinib · 22 Dec 2025

Medicine shortages 5 in the FDA list · 9 German notices

• Rifampin InjectionUS (FDA) · in shortage · updated 18 Sep 2026
• Glyburide TabletUS (FDA) · resolved · updated 10 Aug 2026
• Rifapentine Tablet, Film CoatedUS (FDA) · resolved · updated 6 Aug 2026
• Leflunomide TabletUS (FDA) · resolved · updated 8 Jun 2026
• Doxercalciferol InjectionUS (FDA) · resolved · updated 10 Dec 2025
• L-Thyroxin Henning 75Germany (BfArM) · 19 Aug 2026 to 7 Oct 2026
• NexviadymeGermany (BfArM) · 3 Jul 2026 to 31 Dec 2026
• NexviadymeGermany (BfArM) · 3 Jul 2026 to 31 Dec 2026
• NexviadymeGermany (BfArM) · 3 Jul 2026 to 31 Dec 2026
• XenpozymeGermany (BfArM) · 26 Oct 2026 to 31 Dec 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 39 of its medicines · 32 current

• Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation)NICE TA1187 · Terminated (no company submission) · 20 Aug 2026
• Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetesNICE TA1176 · Recommended · 9 Jul 2026
• Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsNICE TA1142 · Optimised · 26 Mar 2026
• Dupilumab for treating severe chronic rhinosinusitis with nasal polypsNICE TA1134 · Optimised · 18 Feb 2026
• Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)NICE TA1104 · Terminated (no company submission) · 22 Oct 2025
• Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableNICE TA1098 · Recommended · 24 Sep 2025
• Dupilumab for treating moderate to severe prurigo nodularisNICE TA955 · Not recommended · 13 Mar 2024
• Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overNICE TA949 · Recommended · 7 Feb 2024

Appraisals of medicines whose first EU or US authorisation was held by this company, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Sanofi): founded 2004, headquarters Paris, website sanofi.com. Wikidata Q158205 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Sanofi; Genzyme, a Sanofi Company; Sanofi Pasteur, a Sanofi Company; Sanofi-Aventis Recherche & Developpement; Sanofi Vaccines US Inc.; Sanofi Pasteur Inc. and 16 more. Spot a wrong match? Tell us.

Group figures for Sanofi, the parent company. From the annual reports Sanofi files with the US Securities and Exchange Commission (20-F, IFRS), in EUR as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 3 active in the CRO register · 3 dissolved not shown

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Sanofi as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.